Adial Pharmaceuticals, Inc.
ADIL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001513525
In the last 90 days, Adial Pharmaceuticals, Inc. insiders filed 3 open-market purchases and 0 sales; 17 institutions reported holding it in 13F filings for Q2 2026, worth $334.6K in total; no superinvestor holds it.
13F holders, Q1 2025
Institutional positions in Adial Pharmaceuticals, Inc. as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 14
- −1 vs. Q4 2024
- Shares held
- 240.3K
- −55.0K (−18.6%) vs. Q4 2024
- Total value
- $152.7K
- −$145.4K (−48.8%) vs. Q4 2024
- New holders
- 2
- 4 more added
- Sold out
- 3
- 1 more reduced
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ADIL on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 17 | $334.6K |
| Q1 2026 | 15 | $63.8K |
| Q4 2025 | 24 | $778.4K |
| Q3 2025 | 17 | $214.8K |
| Q2 2025 | 17 | $70.8K |
| Q1 2025 | 14 | $152.7K |
| Q4 2024 | 15 | $298.1K |
| Q3 2024 | 12 | $195.9K |
| Q2 2024 | 16 | $328.0K |
| Q1 2024 | 16 | $236.2K |
| Q4 2023 | 17 | $495.3K |
| Q3 2023 | 11 | $164.2K |
| Q2 2023 | 21 | $488.2K |
| Q1 2023 | 23 | $876.9K |
| Q4 2022 | 23 | $359.2K |
| Q3 2022 | 28 | $692.1K |
| Q2 2022 | 26 | $2.27M |
| Q1 2022 | 23 | $6.38M |
| Q4 2021 | 24 | $3.61M |
| Q3 2021 | 21 | $5.50M |
| Q2 2021 | 19 | $3.15M |
| Q1 2021 | 20 | $1.95M |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding Adial Pharmaceuticals, Inc.; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Geode Capital Management, LLC | 68,850 | $43.7K | 0.00% | +7,003+11.3% | Added |
| Manchester Capital Management LLC | 48,097 | $30.5K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 47,745 | $30.3K | 0.00% | +26,727+127.2% | Added |
| BlackRock, Inc. | 27,770 | $17.6K | 0.00% | 00.0% | Unchanged |
| Virtu Financial LLC | 26,414 | $17.0K | 0.00% | +26,414 | New |
| Vanguard Group Inc | 13,159 | $8.34K | 0.00% | +13,159 | New |
| 1620 Investment Advisors, Inc. | 3,600 | $2.28K | 0.00% | 00.0% | Unchanged |
| Raffa Wealth Management, LLC | 2,093 | $1.33K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 1,427 | $905 | 0.00% | +789+123.7% | Added |
| SBI Securities Co., Ltd. | 927 | $588 | 0.00% | −10−1.1% | Reduced |
| Wells Fargo & Company | 160 | $101 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 55 | $35 | 0.00% | +3+5.8% | Added |
| Abound Wealth Management | 27 | $18 | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 9 | $6 | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −54,508−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −47,613−100.0% | Sold out |
| Cambridge Investment Research Advisors, Inc. | 0 | $0 | 0.00% | −27,000−100.0% | Sold out |